All Posts
A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma (HELIX-ICC)
Study Name A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given…
Five for Friday - 5 Events to Add to Your Calendar
Home / COVID-19 / [wpbb post:title] The future is looking bright at the Cholangiocarcinoma Foundation thanks to YOU! We have…
Barbara Ellen Clay
Barbara Ellen Clay 9/16/1937 - 8/11/2020 "A Blessed Life" Click here to contribute in the name of [wpbb post:title] If…
Moving for the Cure Recap
TeamCCF and the Cholangiocarcinoma Foundation held its first-ever virtual athletic fundraising event, Moving for the Cure, the week of July…
Five for Friday - 5 tips on how to get behind Biomarkers Matter
Home / COVID-19 / [wpbb post:title] Cholangiocarcinoma Foundation (CCF) is a proud member of The Working Consistent Group. Together with…
Webinar: "Should I get a second opinion?"
Subscribe to our YouTube Channel Michelle Trachtman, Executive Director of Mike Shane Memorial Fund, will share updates and answer questions.…
TAS-120-301(FOENIX-CCA3)
Study Name TAS-120-301(FOENIX-CCA3) ClinicalTrials.gov Identifier (if applicable) NCT04093362 Clinical Trial Category (check all that apply) First Line Therapy Study Center…
Five for Friday - 5 fundraising events
Home / COVID-19 / [wpbb post:title] Our 2020 Annual Conference was unforgettable! We would like to extend our sincerest thanks…
Five for Friday - 5 highlights from the Annual Conference
Home / COVID-19 / [wpbb post:title] Our 2020 Annual Conference was unforgettable! We would like to extend our sincerest thanks…
The 2020 Annual Conference was a Success!
We would like to extend our sincerest thanks to all those who joined us online during the 2020 Virtual Annual…